Nebivolol Desensitizes Myofilaments of a Hypertrophic Cardiomyopathy Mouse Model

Background: Hypertrophic cardiomyopathy (HCM) patients often present with diastolic dysfunction and a normal to supranormal systolic function. To counteract this hypercontractility, guideline therapies advocate treatment with beta-adrenoceptor and Ca2+ channel blockers. One well established pathomec...

Full description

Bibliographic Details
Main Authors: Sabrina Stücker, Nico Kresin, Lucie Carrier, Felix W. Friedrich
Format: Article
Language:English
Published: Frontiers Media S.A. 2017-08-01
Series:Frontiers in Physiology
Subjects:
Online Access:http://journal.frontiersin.org/article/10.3389/fphys.2017.00558/full
id doaj-f9caa2dc703c45c99447caab8912677d
record_format Article
spelling doaj-f9caa2dc703c45c99447caab8912677d2020-11-25T00:53:16ZengFrontiers Media S.A.Frontiers in Physiology1664-042X2017-08-01810.3389/fphys.2017.00558278557Nebivolol Desensitizes Myofilaments of a Hypertrophic Cardiomyopathy Mouse ModelSabrina Stücker0Sabrina Stücker1Nico Kresin2Nico Kresin3Lucie Carrier4Lucie Carrier5Felix W. Friedrich6Felix W. Friedrich7Department of Experimental Pharmacology and Toxicology, Cardiovascular Research Center, University Medical Center Hamburg-EppendorfHamburg, GermanyGerman Centre for Cardiovascular Research (DZHK)Hamburg, GermanyDepartment of Experimental Pharmacology and Toxicology, Cardiovascular Research Center, University Medical Center Hamburg-EppendorfHamburg, GermanyGerman Centre for Cardiovascular Research (DZHK)Hamburg, GermanyDepartment of Experimental Pharmacology and Toxicology, Cardiovascular Research Center, University Medical Center Hamburg-EppendorfHamburg, GermanyGerman Centre for Cardiovascular Research (DZHK)Hamburg, GermanyDepartment of Experimental Pharmacology and Toxicology, Cardiovascular Research Center, University Medical Center Hamburg-EppendorfHamburg, GermanyGerman Centre for Cardiovascular Research (DZHK)Hamburg, GermanyBackground: Hypertrophic cardiomyopathy (HCM) patients often present with diastolic dysfunction and a normal to supranormal systolic function. To counteract this hypercontractility, guideline therapies advocate treatment with beta-adrenoceptor and Ca2+ channel blockers. One well established pathomechanism for the hypercontractile phenotype frequently observed in HCM patients and several HCM mouse models is an increased myofilament Ca2+ sensitivity. Nebivolol, a commonly used beta-adrenoceptor antagonist, has been reported to lower maximal force development and myofilament Ca2+ sensitivity in rabbit and human heart tissues. The aim of this study was to evaluate the effect of nebivolol in cardiac muscle strips of an established HCM Mybpc3 mouse model. Furthermore, we investigated actions of nebivolol and epigallocatechin-gallate, which has been shown to desensitize myofilaments for Ca2+ in mouse and human HCM models, in cardiac strips of HCM patients with a mutation in the most frequently mutated HCM gene MYBPC3.Methods and Results: Nebivolol effects were tested on contractile parameters and force-Ca2+ relationship of skinned ventricular muscle strips isolated from Mybpc3-targeted knock-in (KI), wild-type (WT) mice and cardiac strips of three HCM patients with MYBPC3 mutations. At baseline, KI strips showed no difference in maximal force development compared to WT mouse heart strips. Neither 1 nor 10 μM nebivolol had an effect on maximal force development in both genotypes. 10 μM nebivolol induced myofilament Ca2+ desensitization in WT strips and to a greater extent in KI strips. Neither 1 nor 10 μM nebivolol had an effect on Ca2+ sensitivity in cardiac muscle strips of three HCM patients with MYBPC3 mutations, whereas epigallocatechin-gallate induced a right shift in the force-Ca2+ curve.Conclusion: Nebivolol induced a myofilament Ca2+ desensitization in both WT and KI strips, which was more pronounced in KI muscle strips. In human cardiac muscle strips of three HCM patients nebivolol had no effect on myofilament Ca2+ sensitivity.http://journal.frontiersin.org/article/10.3389/fphys.2017.00558/fullnebivololmyofilamentCa2+ sensitivityhypertrophic cardiomyopathyMybpc3mouse
collection DOAJ
language English
format Article
sources DOAJ
author Sabrina Stücker
Sabrina Stücker
Nico Kresin
Nico Kresin
Lucie Carrier
Lucie Carrier
Felix W. Friedrich
Felix W. Friedrich
spellingShingle Sabrina Stücker
Sabrina Stücker
Nico Kresin
Nico Kresin
Lucie Carrier
Lucie Carrier
Felix W. Friedrich
Felix W. Friedrich
Nebivolol Desensitizes Myofilaments of a Hypertrophic Cardiomyopathy Mouse Model
Frontiers in Physiology
nebivolol
myofilament
Ca2+ sensitivity
hypertrophic cardiomyopathy
Mybpc3
mouse
author_facet Sabrina Stücker
Sabrina Stücker
Nico Kresin
Nico Kresin
Lucie Carrier
Lucie Carrier
Felix W. Friedrich
Felix W. Friedrich
author_sort Sabrina Stücker
title Nebivolol Desensitizes Myofilaments of a Hypertrophic Cardiomyopathy Mouse Model
title_short Nebivolol Desensitizes Myofilaments of a Hypertrophic Cardiomyopathy Mouse Model
title_full Nebivolol Desensitizes Myofilaments of a Hypertrophic Cardiomyopathy Mouse Model
title_fullStr Nebivolol Desensitizes Myofilaments of a Hypertrophic Cardiomyopathy Mouse Model
title_full_unstemmed Nebivolol Desensitizes Myofilaments of a Hypertrophic Cardiomyopathy Mouse Model
title_sort nebivolol desensitizes myofilaments of a hypertrophic cardiomyopathy mouse model
publisher Frontiers Media S.A.
series Frontiers in Physiology
issn 1664-042X
publishDate 2017-08-01
description Background: Hypertrophic cardiomyopathy (HCM) patients often present with diastolic dysfunction and a normal to supranormal systolic function. To counteract this hypercontractility, guideline therapies advocate treatment with beta-adrenoceptor and Ca2+ channel blockers. One well established pathomechanism for the hypercontractile phenotype frequently observed in HCM patients and several HCM mouse models is an increased myofilament Ca2+ sensitivity. Nebivolol, a commonly used beta-adrenoceptor antagonist, has been reported to lower maximal force development and myofilament Ca2+ sensitivity in rabbit and human heart tissues. The aim of this study was to evaluate the effect of nebivolol in cardiac muscle strips of an established HCM Mybpc3 mouse model. Furthermore, we investigated actions of nebivolol and epigallocatechin-gallate, which has been shown to desensitize myofilaments for Ca2+ in mouse and human HCM models, in cardiac strips of HCM patients with a mutation in the most frequently mutated HCM gene MYBPC3.Methods and Results: Nebivolol effects were tested on contractile parameters and force-Ca2+ relationship of skinned ventricular muscle strips isolated from Mybpc3-targeted knock-in (KI), wild-type (WT) mice and cardiac strips of three HCM patients with MYBPC3 mutations. At baseline, KI strips showed no difference in maximal force development compared to WT mouse heart strips. Neither 1 nor 10 μM nebivolol had an effect on maximal force development in both genotypes. 10 μM nebivolol induced myofilament Ca2+ desensitization in WT strips and to a greater extent in KI strips. Neither 1 nor 10 μM nebivolol had an effect on Ca2+ sensitivity in cardiac muscle strips of three HCM patients with MYBPC3 mutations, whereas epigallocatechin-gallate induced a right shift in the force-Ca2+ curve.Conclusion: Nebivolol induced a myofilament Ca2+ desensitization in both WT and KI strips, which was more pronounced in KI muscle strips. In human cardiac muscle strips of three HCM patients nebivolol had no effect on myofilament Ca2+ sensitivity.
topic nebivolol
myofilament
Ca2+ sensitivity
hypertrophic cardiomyopathy
Mybpc3
mouse
url http://journal.frontiersin.org/article/10.3389/fphys.2017.00558/full
work_keys_str_mv AT sabrinastucker nebivololdesensitizesmyofilamentsofahypertrophiccardiomyopathymousemodel
AT sabrinastucker nebivololdesensitizesmyofilamentsofahypertrophiccardiomyopathymousemodel
AT nicokresin nebivololdesensitizesmyofilamentsofahypertrophiccardiomyopathymousemodel
AT nicokresin nebivololdesensitizesmyofilamentsofahypertrophiccardiomyopathymousemodel
AT luciecarrier nebivololdesensitizesmyofilamentsofahypertrophiccardiomyopathymousemodel
AT luciecarrier nebivololdesensitizesmyofilamentsofahypertrophiccardiomyopathymousemodel
AT felixwfriedrich nebivololdesensitizesmyofilamentsofahypertrophiccardiomyopathymousemodel
AT felixwfriedrich nebivololdesensitizesmyofilamentsofahypertrophiccardiomyopathymousemodel
_version_ 1725238406972178432